A review on comparative study of effectiveness of pregabalin and carbamazepine in painful diabetic peripheral neuropathy using mc gill's pain questionnaire
1 Department of Pharmaceutics, Ratnam Institute of Pharmacy, Pidathapolur Village and Post, Muthukur (M), SPSR Nellore, Andhra Pradesh 524346.
2 Doctor of Pharmacy, Ratnam Institute of Pharmacy, Pidathapolur Village and Post, Muthukur (M), SPSR Nellore, Andhra Pradesh 524346.
3 Department of Pharmacology, Ratnam Institute of Pharmacy, Pidathapolur Village and Post, Muthukur (M), SPSR Nellore, Andhra Pradesh 524346.
Review Article
World Journal of Advanced Research and Reviews, 2024, 21(03), 133–137
Publication history:
Received on 06 January 2024; revised on 14 February 2024; accepted on 16 February 2024
Abstract:
Diabetic neuropathy is a unique degenerative disorder of the peripheral nervous system that preferentially targets sensory axons and autonomic axons. The loss of sensory function that begins distally in the lower extremities is known as Diabetic neuropathy. It is characterized by burning pain, paresthesias and numbness in stocking glove pattern that progress proximally from the feet and hands. Diabetic neuropathy is a highly prevalent condition that substantially affects patients by increasing falls causing pain and reducing quality of life. The major risk factors for diabetic neuropathy is hyperglycemia. In addition to poor glycemic control, more-severe symptoms of diabetic neuropathy are associated with advanced age, hypertension, the duration of diabetes, dyslipidemia, smoking and heavy alcohol intake. Diabetic neuropathy is a major cause for disability of feet and hands globally. Anti-convulsants like pregabalin and carbamazepine are the medications used in the treatment of painful diabetic neuropathy.
Keywords:
Peripheral neuropathy; Diabetes Mellitus; Pregabalin; Carbamazepine; Mc Gill pain questionnaire
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0